Continuing a trend that began in 2017, this year has seen the rise of big investment deals in the biotech sector. Smaller biotechs are also cashing in as Big Pharma look to fill dwindling pipelines; according to Bloomberg data, biotech acquisitions are expected to be at the highest level for 12 years. Analysing this data from … Continue reading Whitepaper: The Rise of Bigger, Earlier M&A Deals for Biotech
Current transfusion medicine entirely relies on donated blood. Megakaryon will change the transfusion practices by supplying safe and cost-saving platelets produced in vitro. Mass production in Japan is expected to begin in 2020. Venture Valuation (VV) interviewed Genjiro Miwa, CEO and Founder. Read the interview
Leveraging its proprietary technology of culturing highly purified dendritic cells (DCs), tella is developing, as its first immunotherapeutic product, a DC-based vaccine in combination with WT1 (Wilms’ tumor gene 1) antigen for inoperable pancreatic cancer. Venture Valuation (VV) interviewed Dr. Yuichiro Yazaki, President and CEO. Read the interview
Zurich, Edmonton January 2018 BioAlberta, a Canadian life sciences industry organization, has recently become a new business partner of Venture Valuation/Biotechgate. BioAlberta gathers a flourishing biotech community comprised of around 170 life sciences companies, government organizations, support service providers, and research & academic institutions, situated across the province. As per the partnership agreement, Venture Valuation … Continue reading The Launch of the BioAlberta Life Sciences Database
Zurich/Vancouver January 2018 Biotechgate/Venture Valuation announce entering a partnership with Life Sciences British Columbia, a Canadian non-profit organization. The goal of the partnership is to develop and run a database comprised of the life science companies situated in the province of British Columbia. The database will be integrated into the Life Sciences BC website (lifesciencesbc.ca) … Continue reading Life Sciences BC – New Canadian Partner for Venture Valuation/Biotechgate
Dr. Patrik Frei was the keynote speaker at BIO IP & Diagnostics Symposium (IPDx) on 29th of September 2017. During the session, the Venture Valuation CEO discussed the valuation of biotechnology companies and products and its link to IP. He gave a short introduction to risk-adjusted net present value calculations, the main value drivers and … Continue reading BIO IP & Diagnostics Symposium (IPDx) Keynote Session
During the last RESI (Redefining Early Stage Investments) Conference – the event series organized by Life Science Nation, a Venture Valuation long-time partner – Dr. Patrik Fried delivered a session on life science deal and product valuations. The notes from the workshop are available to download here
Inventiveness in peptide drug technology and a well thought- out business strategy characterize PeptiDream’s thriving growth. Venture Valuation (VV) interviewed Kiichi Kubota, co-founder and Chairman. Read the interview
